Movement Alert｜Arrowhead Pharmaceuticals Falls 6.92% in Regular Trading, Trading at $66.71

Market Focus09-24

On September 24, Arrowhead Pharmaceuticals fell 6.92% in regular trading, trading at $66.71 USD/share, with Turnover of $46.36 million.

Within the Biotechnology sector where Arrowhead Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, Moderna up 1.1%, Greenland Mines down 13.99%, Amgen down 1.25%, Viking Therapeutics up 0.2%, AbbVie down 0.16%.

Arrowhead Pharmaceuticals, Inc. develops medicines based on RNA interference (RNAi) mechanisms to treat intractable diseases. The company currently has multiple candidates across Phase 1 through Phase 3 clinical trials, spanning therapeutic areas including cardiovascular metabolic diseases, liver diseases, and pulmonary conditions. Its lead product Redemplo (Plozasiran) has received EU marketing authorization for familial chylomicronaemia syndrome and is commercially available in Germany, with a supplemental NDA submission for severe hypertriglyceridemia planned before year-end using a priority review voucher.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106186610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106186610","market":"us","top_or_hot":-1,"title":"Movement Alert｜Arrowhead Pharmaceuticals Falls 6.92% in Regular Trading, Trading at $66.71","media":"Market Focus","content":"<p><p>On September 24, Arrowhead Pharmaceuticals fell 6.92% in regular trading, trading at $66.71 USD/share, with Turnover of $46.36 million.</p><p>Within the Biotechnology sector where Arrowhead Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, Moderna up 1.1%, Greenland Mines down 13.99%, Amgen down 1.25%, Viking Therapeutics up 0.2%, AbbVie down 0.16%.</p><p>Arrowhead Pharmaceuticals, Inc. develops medicines based on RNA interference (RNAi) mechanisms to treat intractable diseases. The company currently has multiple candidates across Phase 1 through Phase 3 clinical trials, spanning therapeutic areas including cardiovascular metabolic diseases, liver diseases, and pulmonary conditions. Its lead product Redemplo (Plozasiran) has received EU marketing authorization for familial chylomicronaemia syndrome and is commercially available in Germany, with a supplemental NDA submission for severe hypertriglyceridemia planned before year-end using a priority review voucher.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Arrowhead Pharmaceuticals Falls 6.92% in Regular Trading, Trading at $66.71</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Arrowhead Pharmaceuticals Falls 6.92% in Regular Trading, Trading at $66.71\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-24 00:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 24, Arrowhead Pharmaceuticals fell 6.92% in regular trading, trading at $66.71 USD/share, with Turnover of $46.36 million.</p><p>Within the Biotechnology sector where Arrowhead Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, Moderna up 1.1%, Greenland Mines down 13.99%, Amgen down 1.25%, Viking Therapeutics up 0.2%, AbbVie down 0.16%.</p><p>Arrowhead Pharmaceuticals, Inc. develops medicines based on RNA interference (RNAi) mechanisms to treat intractable diseases. The company currently has multiple candidates across Phase 1 through Phase 3 clinical trials, spanning therapeutic areas including cardiovascular metabolic diseases, liver diseases, and pulmonary conditions. Its lead product Redemplo (Plozasiran) has received EU marketing authorization for familial chylomicronaemia syndrome and is commercially available in Germany, with a supplemental NDA submission for severe hypertriglyceridemia planned before year-end using a priority review voucher.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1106186610","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106186610","pubTimestamp":1790180072,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 24, Arrowhead Pharmaceuticals fell 6.92% in regular trading, trading at $66.71 USD/share, with Turnover of $46.36 million.Within the Biotechnology sector where Arrowhead Pharmaceuticals...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"走势提醒|Arrowhead Pharmaceuticals 常规交易中下跌 6.92%，交易价格为 66.71 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"On September 24, Arrowhead Pharmaceuticals fell 6.92% in regular trading, trading at $66.71 USD/share, with Turnover of $46.36 million.Within the Biotechnology sector where Arrowhead Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, Moderna up 1.1%, Greenland Mines down 13.99%, Amgen down 1.25%, Viking Therapeutics up 0.2%, AbbVie down 0.16%.Arrowhead Pharmaceuticals, Inc. develops medicines based on RNA interference (RNAi) mechanisms to treat intractable diseases. The company currently has multiple candidates across Phase 1 through Phase 3 clinical trials, spanning therapeutic areas including cardiovascular metabolic diseases, liver diseases, and pulmonary conditions. Its lead product Redemplo (Plozasiran) has received EU marketing authorization for familial chylomicronaemia syndrome and is commercially available in Germany, with a supplemental NDA submission for severe hypertriglyceridemia planned before year-end using a priority review voucher.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106186610","isCrawlerRequest":true}